Inhibrx CEO Mark Lappe reports acquisition of 25,000 common shares worth $2.59 million - INBX News | RalliesInhibrx CEO Mark Lappe reports acquisition of 25,000 common shares worth $2.59 million
I
INBX• CEO reports open-market share purchases
- Inhibrx Biosciences CEO Mark Lappe reported open-market purchases totaling 25,000 common shares at weighted-average prices of $99.29 to $112.28.
- Holdings in the Lappe Family Trust rose to 730,548 shares following the purchases.
- Separate indirect holdings listed 165,000 shares in a descendants’ trust, plus 54,865 shares in a Roth IRA.
•
